login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
All US stocks
All Canadian stocks
All European stocks
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Account
Disclaimer
Affiliate
Contact
Privacy
Alder Biopharmaceuticals Inc (ALDR) Stock News
NASDAQ:ALDR - Nasdaq -
18.88
-0.04 (-0.21%)
After market: 18.88
0 (0%)
Summary
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
ALDR Latest News, Press Relases and Analysis
All
Press Releases
6 years ago - By: Analyst Ratings
Mizuho Securities Sticks to Its Hold Rating for Alder Biopharmaceuticals (ALDR)
6 years ago - By: Benzinga
- Mentions:
UMH
AAPL
AMKR
AMWD
...
Stocks That Hit 52-Week Highs On Monday
6 years ago - By: Benzinga
- Mentions:
AMZN
COST
HOME
HD
...
Jim Cramer Shares His Thoughts On Canopy Growth, Procter & Gamble And More
6 years ago - By: Zacks Investment Research
- Mentions:
GM
NEWR
SEMG
Company News For Sep 17, 2019
6 years ago - By: Rigrodsky & Long P.A.
ALDER BIOPHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout
6 years ago - By: The Street
- Mentions:
SHOP
CGC
TMO
HOME
...
Canopy Growth, Shopify, Thermo Fisher Scientific: 'Mad Money' Lightning Round
6 years ago - By: Zacks Investment Research
All You Need to Know About Alder BioPharmaceuticals (ALDR) Rating Upgrade to Strong Buy
6 years ago - By: The Motley Fool
Here's Why Alder Biopharmaceuticals More Than Doubled in September
6 years ago - By: The Schall Law Firm
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Alder BioPharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
6 years ago - By: Zacks Investment Research
- Mentions:
AMWD
DKS
COLM
LPTX
Zacks.com featured highlights include: Columbia Sportswear, American Woodmark, DICK'S Sporting, Alder and Leap
6 years ago - By: Zacks Investment Research
- Mentions:
AMWD
DKS
COLM
LPTX
Use Rising P/E Strategy to Grab 5 Winning Stocks
6 years ago - By: Investor's Business Daily
- Mentions:
WVE
SRPT
MRK
BIIB
...
Biotechs Fly Sideways In Quiet Week — 5 News Items You May Have Missed
6 years ago - By: Investor's Business Daily
- Mentions:
MSFT
FDX
GM
ROKU
...
Stock Market Steady Amid Soaring Crude Oil Prices, Fed Rate Cut; Microsoft, Adobe, FedEx, GM, Roku In Focus: Weekly Review
6 years ago - By: Zacks Investment Research
- Mentions:
CELG
ALXN
XLRN
AIMT
...
Biotech Stock Roundup: BIIB Halts AD Study, AMGN Posts Positive MM Drug Data & More
6 years ago - By: WeissLaw LLP
SHAREHOLDER ALERT: WeissLaw LLP Investigates Alder Biopharmaceuticals, Inc.
6 years ago - By: Zacks Investment Research
- Mentions:
LLY
NVS
AMGN
Alder (ALDR) Stock Up on Acquisition Agreement With Lundbeck
6 years ago - By: StockNews.com
- Mentions:
WINS
SEMG
AMR
WLL
...
Best & Worst Performing Small Cap Stocks for September 16, 2019
6 years ago - By: The Motley Fool
- Mentions:
COP
SEMG
ET
Why ConocoPhillips, Alder BioPharmaceuticals, and SemGroup Jumped Today
6 years ago - By: MarketJar
ALDR Stock Hits 2-Year High on Lundbeck Acquisition News
6 years ago - By: Bragar Eagel & Squire, P.C.
Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR) on Behalf of Alder Shareholders and Encourages Alder Investors to Contact the Firm
Please enable JavaScript to continue using this application.